The proposed Center for Excellence in Translational Research combines 4 related endeavors focused in the development of a rapid molecular diagnostic with which to diagnosed first and second line drug resistance to Mycobacteria tuberculosis. The administrative core of this center provide scientific leadership and support for the center through the PI and Scientific Advisory Board consulting closely with the research project Pis and collaborators. The core will provide administrative support to each ofthe 4 research projects and the Sequencing core including negotiation, execution, and monitoring of sub-contracts and consulting agreements, financial monitoring and invoice tracking, communications platforms and plans including project website and portal for dissemination and storage of key center documents, teleconference/videoconference/web-conference infrastructure, centralized scheduling of teleconferences and meetings and travel and meeting logistics . The core will also provide continuous monitoring and evaluation ofthe progress ofthe projects through tracking of milestones and will ensure project regulatory compliance for human subjects, animal protocols and BSL3 biosafety standards. Lastly, the core will work with the Scientific Advisory Committee to solicit and review Supplementary projects aligned to the goals of the Center.

Public Health Relevance

By supporting the activities of this Center, the Administrative Core will contribute to the development of a rapid diagnostic test that will enable early diagnosis and appropriate treatment of drug resistant TB.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109755-01
Application #
8653814
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$225,640
Indirect Cost
$34,448
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Gong, Lingyan; Ouyang, Wei; Li, Zirui et al. (2017) Force fields of charged particles in micro-nanofluidic preconcentration systems. AIP Adv 7:125020
Ouyang, Wei; Han, Jongyoon; Wang, Wei (2017) Nanofluidic crystals: nanofluidics in a close-packed nanoparticle array. Lab Chip 17:3006-3025
Ouyang, Wei; Han, Jongyoon; Wang, Wei (2017) Enabling electrical biomolecular detection in high ionic concentrations and enhancement of the detection limit thereof by coupling a nanofluidic crystal with reconfigurable ion concentration polarization. Lab Chip 17:3772-3784
Rock, Jeremy M; Hopkins, Forrest F; Chavez, Alejandro et al. (2017) Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat Microbiol 2:16274
Yadon, Adam N; Maharaj, Kashmeel; Adamson, John H et al. (2017) A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun 8:588
Calderón, R I; Velásquez, G E; Becerra, M C et al. (2017) Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis 21:894-901
Velásquez, Gustavo E; Calderon, Roger I; Mitnick, Carole D et al. (2017) Erratum for Velásquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 61:
Velásquez, Gustavo E; Calderon, Roger I; Mitnick, Carole D et al. (2016) Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother 60:6766-6773
Farhat, Maha R; Jacobson, Karen R; Franke, Molly F et al. (2016) Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol 54:727-33
Farhat, M R; Mitnick, C D; Franke, M F et al. (2015) Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment. Int J Tuberc Lung Dis 19:339-41

Showing the most recent 10 out of 12 publications